Replies to post #563 on Bristol Myers Squibb (BMY)

[Johnny_C]

Hard to swallow that in less than an hour volume tripled over NVS news. The drop in PPS has ticked some off but the earnings 2 out of the last 3 Q's have been great. They increased guidance, have a robust pipeline in oncology. Eliquis is still growing. Dividends conservatively increased over the last 7 years. It is still the 8th largest pharma. Not the most exciting company. Good cash position vs low debt.

Good buying opportunity whether buyout happens or not.